On June 23, 2022 Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, reported that new data on the mechanism of action of its lead clinical candidate BTM-3566 will be presented at the Third AACR (Free AACR Whitepaper) International Meeting – Advances in Malignant Lymphoma taking place on the 23-26 June in Boston (Press release, Bantam Pharmaceutical, JUN 23, 2022, View Source;advances-in-malignant-lymphoma-301573728.html [SID1234616219]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The studies evaluated the activity of BTM-3566 in tumor lines in vitro and in vivo while further elucidating the mechanism of action.
A PDF of the poster will be available on the Bantam website following the conference.
Michael Stocum, CEO of Bantam Pharmaceutical, commented: "Our data demonstrate exceptional single-agent activity in patient derived xenograft models of difficult-to-treat lymphomas. We are excited to bring this novel mechanism of action to the clinic in the coming months and explore its value as a treatment for relapsed and refractory DLBCL."
Title: Pharmacological activation of the mitochondrial protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma
About BTM-3566
BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique and differentiated from other therapeutics, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is being completed with plans to initiate First in Human trials in lymphoma patients in the fall of 2022.